Neurogene Inc. Expected to Post Q2 2024 Earnings of ($1.19) Per Share (NASDAQ:NGNE)

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at Leerink Partnrs issued their Q2 2024 earnings per share (EPS) estimates for shares of Neurogene in a note issued to investors on Monday, April 29th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings of ($1.19) per share for the quarter. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($3.98) per share. Leerink Partnrs also issued estimates for Neurogene’s Q3 2024 earnings at ($1.22) EPS, Q4 2024 earnings at ($1.23) EPS, FY2024 earnings at ($4.82) EPS, FY2025 earnings at ($4.43) EPS and FY2026 earnings at ($5.04) EPS.

Other research analysts also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Neurogene in a research report on Friday. Stifel Nicolaus started coverage on Neurogene in a report on Friday, January 5th. They issued a “buy” rating and a $31.00 target price on the stock. SVB Leerink started coverage on Neurogene in a research report on Monday, April 29th. They set an “outperform” rating and a $46.00 target price on the stock. Finally, William Blair began coverage on Neurogene in a research report on Thursday, March 21st. They issued an “outperform” rating and a $61.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $48.25.

Neurogene Stock Performance

NGNE opened at $36.63 on Thursday. The business has a 50 day simple moving average of $38.19. The stock has a market capitalization of $471.43 million, a P/E ratio of -2.94 and a beta of 1.36. Neurogene has a 12-month low of $12.20 and a 12-month high of $53.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Privium Fund Management UK Ltd purchased a new position in shares of Neurogene in the first quarter valued at about $274,000. BML Capital Management LLC bought a new stake in Neurogene during the 4th quarter valued at approximately $478,000. Avidity Partners Management LP purchased a new position in Neurogene in the 4th quarter worth approximately $9,036,000. Finally, Great Point Partners LLC bought a new position in Neurogene in the 4th quarter worth approximately $19,268,000. Institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.